1. Introduction {#sec1-ijms-21-04852}
===============

The study of WNT-signaling was initiated in the early 1980′s by the discovery of *Wingless*, a *Drosophila* segment polarity gene \[[@B1-ijms-21-04852]\] and then the mouse proto-oncogene *Int1* \[[@B2-ijms-21-04852]\]. The term 'WNT' comes from a combination of these two names of the same gene \[[@B3-ijms-21-04852]\]. The WNT-signaling is evolutionarily conserved and plays an important role in the embryonic development, adult tissue homeostasis and regeneration \[[@B4-ijms-21-04852]\]. Furthermore, it maintains genetic stability and is important for cell fate and differentiation, cell proliferation, cell motility, apoptosis and stem cell maintenance \[[@B5-ijms-21-04852]\]. Aberrant functioning of WNT-signaling is associated with a number of diseases, including embryonic malformations, degenerative diseases and cancer \[[@B6-ijms-21-04852],[@B7-ijms-21-04852],[@B8-ijms-21-04852],[@B9-ijms-21-04852]\]. WNT-signaling is divided into two pathways: β-catenin-dependent also known as canonical or WNT/β-catenin pathway and β-catenin-independent---also termed as non-canonical---which can be further divided into WNT/planar cell polarity (PCP) and calcium pathway that in some circumstances can antagonize WNT/β-catenin-signaling \[[@B10-ijms-21-04852]\]. The β-catenin-dependent pathway mainly controls cell proliferation, whereas β-catenin-independent signaling regulates cell polarity and migration. This distinction, however, is conventional as these two main pathways form a network with concomitant crosstalk and mutual regulation \[[@B11-ijms-21-04852],[@B12-ijms-21-04852]\]. Better understanding of the mechanisms that govern the highly context-dependent outcome of WNT-signaling in different tumors is important for the development of appropriate treatment strategies. This review is focused on WNT-signaling in melanoma, a tumor derived from melanocytes that arise from neural crest cells.

1.1. WNT Ligands in Canonical and Non-Canonical WNT Signaling Pathways {#sec1dot1-ijms-21-04852}
----------------------------------------------------------------------

The WNT family of secreted proteins includes 19 cysteine-rich glycoproteins (\~40 kDa; \~350--400 amino acids with a 20--85% sequence identity) \[[@B4-ijms-21-04852],[@B13-ijms-21-04852]\], in which postranslational modifications comprising glycosylation and palmitoylation are considered to be essential for their biologic activity \[[@B6-ijms-21-04852],[@B14-ijms-21-04852]\]. Porcupine, endoplasmic reticulum resident acyltransferase, is the enzyme that is required for the attachment of palmitoleic acid to WNT ligands \[[@B6-ijms-21-04852],[@B8-ijms-21-04852],[@B14-ijms-21-04852]\]. Then, WNT ligands bind to an evolutionary highly conserved transmembrane protein Evenness interrupted/Wntless (EVI/WLS) and are shuttled to the plasma membrane via the Golgi apparatus \[[@B15-ijms-21-04852]\]. By clathrin-mediated endocytosis, EVI/WLS is recycled in the Golgi apparatus by the retromer complex. There are several routes enabling WNT proteins to exit the cells: by solubilization, exosome formation or by lipoprotein particles (LPPs), serving as extracellular transporters to achieve long-range signaling \[[@B4-ijms-21-04852],[@B8-ijms-21-04852],[@B15-ijms-21-04852]\]. The interactions between WNTs and their specific receptors activate WNT pathways: canonical (β-catenin-dependent) ([Figure 1](#ijms-21-04852-f001){ref-type="fig"}) and non-canonical (β-catenin-independent) ([Figure 2](#ijms-21-04852-f002){ref-type="fig"}) that cooperate with each other in regulation of important cellular processes. Generally, the ligand subtype determines the mode of the WNT-signaling network. WNT1, WNT2, WNT3, WNT3A, WNT8a, WNT8b, WNT10a and WNT10b are activators of the canonical pathway, whereas WNT4, WNT5A, WNT5B, WNT6, WNT7a, WNT7b and WNT11 are common activators of non-canonical WNT-signaling \[[@B16-ijms-21-04852],[@B17-ijms-21-04852]\]. WNTs are classified as directional growth factors with unique properties since they influence proliferation and polarity, and both may occur at the same time and in the same cells \[[@B18-ijms-21-04852]\]. Moreover, WNTs can act in an autocrine and paracrine manner \[[@B6-ijms-21-04852],[@B19-ijms-21-04852],[@B20-ijms-21-04852]\].

1.2. β-Catenin-Dependent (Canonical) WNT Signaling {#sec1dot2-ijms-21-04852}
--------------------------------------------------

In resting cells, in the absence of activating signals ([Figure 1](#ijms-21-04852-f001){ref-type="fig"}A), the level of β-catenin is low, which is achieved by the cytoplasmic 'destruction complex' that consists of axis inhibition protein 1 (AXIN1), adenomatosis polyposis coli (APC), glycogen synthase kinase 3β (GSK3β) and casein kinase 1α (CK1α) \[[@B7-ijms-21-04852],[@B21-ijms-21-04852],[@B22-ijms-21-04852],[@B23-ijms-21-04852]\]. AXIN1 is the central scaffold protein, which directly interacts with all other core components of the destruction complex \[[@B24-ijms-21-04852]\]. It is a concentration-limiting protein \[[@B25-ijms-21-04852]\], and its cellular level is stabilized by SUMOylation \[[@B26-ijms-21-04852]\] and decreased by degradation involving activated low-density lipoprotein receptor related protein 5/6 (LRP5/6) \[[@B27-ijms-21-04852]\] and tankyrases \[[@B28-ijms-21-04852]\]. Affinity of AXIN1 to β-catenin is increased by GSK3β-mediated phosphorylation \[[@B29-ijms-21-04852],[@B30-ijms-21-04852]\]. In the destruction complex, β-catenin is first phosphorylated by CK1α at Ser45, then by a serine/threonine kinase GSK3β at Ser 33, Ser 37 and Thr41. Interaction of GSK3β with β-catenin is facilitated by AXIN1 and APC \[[@B29-ijms-21-04852],[@B31-ijms-21-04852]\]. F-box containing protein E3 ubiquitin ligases such as β-transducin repeat-containing protein (β-TrCP) marks β-catenin for ubiquitination and proteasomal degradation \[[@B4-ijms-21-04852],[@B22-ijms-21-04852],[@B23-ijms-21-04852],[@B32-ijms-21-04852]\].

Upon binding of WNT proteins to the seven-pass transmembrane frizzled (FZD) receptor and single pass transmembrane receptors LRP5 and LRP6, the initiation of canonical signaling pathway occurs, leading to β-catenin stabilization ([Figure 1](#ijms-21-04852-f001){ref-type="fig"}B) \[[@B7-ijms-21-04852],[@B32-ijms-21-04852]\]. A characteristic feature of FZD is the cysteine-rich domain, which is the primary module for binding of WNT ligands \[[@B4-ijms-21-04852],[@B13-ijms-21-04852]\]. The mutual interaction of WNT ligands with both FZD and LRP5/6 is necessary for canonical pathway activation that inhibits β-catenin proteasomal degradation \[[@B7-ijms-21-04852],[@B22-ijms-21-04852],[@B32-ijms-21-04852]\]. It is preceded by a series of events, and several models have been created \[[@B33-ijms-21-04852]\] to show the sequence of events leading to activation of β-catenin. Regardless of the model, disheveled (DVL) that directly interacts with FZD is concomitantly phosphorylated by several protein kinases such as protease-activated receptor 1 (PAR1), casein kinase 1ε (CK1ε), metastasis associated kinase (MAK) and protein kinase C (PKC) \[[@B14-ijms-21-04852],[@B34-ijms-21-04852]\]. Activated DVL detaches AXIN1 from the destruction complex and the released AXIN1 binds to phosphorylated LRP5/6 \[[@B7-ijms-21-04852],[@B32-ijms-21-04852]\]. Phosphorylation of LRP5 and LRP6 occurs in Pro-Pro-Pro(SerTrp)Pro (PPP(S/T)P) motifs and is triggered by GSK3β and CK1γ \[[@B23-ijms-21-04852],[@B34-ijms-21-04852]\]. β-catenin can be dephosphorylated by protein phosphatase 2A (PP2A) \[[@B35-ijms-21-04852]\]. WNT/β-catenin-signaling can be potentiated by the leucine-rich repeat-containing G-protein coupled receptor 5/a roof plate-specific spondin (LGR5/RSPO) complex, which acts in cooperation with receptors FZD/LRP5/6 \[[@B36-ijms-21-04852],[@B37-ijms-21-04852],[@B38-ijms-21-04852]\]. The LRG5/RSPO complex promotes WNT-signaling through the neutralization ring finger protein 43 (RNF43) and zinc and ring finger protein 3 (ZNRF3), the transmembrane E3 ligases that serve as a part of a negative feedback loop \[[@B39-ijms-21-04852]\]. All these processes lead to the accumulation of stable, unphosphorylated β-catenin in the cytoplasm, followed by its translocation to the nucleus. β-catenin binds to nucleoporins (NUPs) and builds the nuclear pore complex (NPC). It binds NUP358 on the cytoplasmic side, NUP62 in a central channel and NUP98 together with NUP153 on a nuclear end \[[@B40-ijms-21-04852]\]. In the nucleus, after displacing the transcriptional repressor Groucho, β-catenin can interact with several proteins, e.g., T cell factor/lymphoid enhancer-binding factor 1 (TCF/LEF), brahma-related gene-1 (BRG-1), TATA-binding protein, CREB-binding protein/its homolog p300 (CBP/p300), c-JUN, SWItch/sucrose non-fermentable chromatin-remodeling complex (SWI/SNF) and B-cell CLL/lymphoma 9 protein (BCL-9; BCL9L), which links the N terminal part of β-catenin with pygopus (PYGO) \[[@B34-ijms-21-04852],[@B41-ijms-21-04852]\]. Then, β-catenin serves as a transcriptional regulator of the expression of WNT target genes \[[@B7-ijms-21-04852],[@B21-ijms-21-04852],[@B32-ijms-21-04852],[@B34-ijms-21-04852]\]. These genes encode the following groups of proteins: (a) regulators of proliferation, e.g., vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), c-JUN, FOS-related antigen 1 (FRA1); (b) regulators of the canonical WNT pathway e.g., WNT1-inducible-signaling pathway protein 1 (WISP1), AXIN, Dickkopf-1 (DKK1), TCF, LEF1; (c) matrix metalloproteinases and some components of extracellular matrix; (d) cadherins; (e) lineage-specific proteins such as microphthalmia-associated transcription factor (MITF), which modulates several functions in melanocytes and melanoma \[[@B42-ijms-21-04852]\].

It should be noted that the transcriptional role of β-catenin extends beyond the TCF/LEF as β-catenin may be a partner of other transcription factors, e.g., sex-determining region Y (SRY) box-containing factors (SOX), mothers against decapentaplegic homolog (SMAD), octamer-binding transcription factor 4 (OCT4) and forkhead box class O family member proteins (FOXOs) \[[@B43-ijms-21-04852]\].

WNT/β-catenin-signaling can be modulated by several antagonists at the ligand and receptor level, e.g., DKK proteins, secreted frizzled-related proteins (sFRPs), WNT inhibitory factor 1 (WIF1), WNT modulator in surface ectoderm (WISE), Kremen (KRM) and Cerberus protein (CER1) \[[@B14-ijms-21-04852],[@B16-ijms-21-04852],[@B44-ijms-21-04852]\]. They interact with WNTs and their receptors, causing the inhibition of the WNT/β-catenin pathway \[[@B16-ijms-21-04852]\]. Moreover, the activity of WNTs is also modulated by a highly conserved feedback antagonist NOTUM, acting as a deacylase that removes a palmitate moiety from WNTs leading to their inactivation \[[@B4-ijms-21-04852]\]. There are several negative feedback mechanisms that can limit WNT-signaling, including WNT target genes such as *AXIN1, AXIN2, DKK1* and *SFRP* \[[@B45-ijms-21-04852],[@B46-ijms-21-04852]\].

The β-catenin-dependent WNT-signaling cascade ([Figure 1](#ijms-21-04852-f001){ref-type="fig"}) regulates a wide range of biologic processes comprising both developmental processes during embryogenesis as well as those during tissue homeostasis and regeneration. Canonical WNT-signaling is involved in the regulation of cell proliferation and differentiation and maintenance of stem cells. β-catenin, the central component of WNT/β-catenin pathway is a multifunctional protein that can either bind to cadherin that is an integral part of the actin cytoskeleton or act as transcriptional coactivator \[[@B42-ijms-21-04852],[@B47-ijms-21-04852]\]. β-catenin is expressed both in melanocytes and epithelium, however, the amount of β-catenin at the cell surface is less abundant in melanocytes than in epithelial cells \[[@B48-ijms-21-04852]\]. β-catenin (781 amino acids) is encoded by *CTNNB1* and comprises a flexible N-terminal domain (NTD; \~150 aa), central armadillo (ARM) repeat domain (12 copies, 550 aa) and a C-terminal transactivation domain (CTD; \~100 aa) \[[@B23-ijms-21-04852]\]. While NTD and CTD may be flexible, the central region forms a rigid scaffold that is responsible for the interaction of β-catenin with its binding partners \[[@B49-ijms-21-04852]\] such as cytoskeletal proteins α-catenin, IQ motif containing GTPase activating protein 1(IQGAP1) \[[@B50-ijms-21-04852]\], E-cadherin and N-cadherin \[[@B51-ijms-21-04852]\], a conserved nuclear protein, named chibby, transcriptional regulators TCF/LEF, inhibitor of β-catenin and TCF4 (ICAT) and proteins forming the 'destruction complex'.

1.3. Non-Canonical WNT Signaling {#sec1dot3-ijms-21-04852}
--------------------------------

β-catenin-independent pathways comprise: WNT/planar cell polarity-signaling pathway (PCP) ([Figure 2](#ijms-21-04852-f002){ref-type="fig"}A) and WNT/Ca^2+^-signaling pathway ([Figure 2](#ijms-21-04852-f002){ref-type="fig"}B). The WNT/PCP-signaling pathway maintains planar cell polarity, as it is involved in regulation of modification of actin cytoskeleton structures and cell motility. It is activated by binding of WNT5A, WNT7A and WNT11 ligands to non-canonical FZD receptors along with tyrosine kinase co-receptors: protein tyrosine kinase 7 (PTK7), RAR-related orphan receptor (ROR) and receptor like tyrosine kinase (RYK) \[[@B52-ijms-21-04852]\]. WNT5A is a key regulator of non-canonical WNT-signaling, however, it can play diverse roles in different types of cells, including tumor cells. Different roles of WNT5A, especially in various cancers, are partially due to the existence of two isoforms of WNT5A, WNT5A-long and WNT5-short \[[@B53-ijms-21-04852]\]. Activation of DVL and further formation of the disheveled associated activator of morphogenesis 1 (DVL-Daam-1) complex activates the RHO GTPase that leads to activation of the RHO-associated kinase (ROCK) followed by modification of actin cytoskeleton and cytoskeletal rearrangement. DVL also activates the RAC GTPase that stimulates c-Jun N-terminal kinases (JNK) activity, which in turn positively regulates activator protein 1 (AP-1)-dependent genes. This network is involved in the modification of actin cytoskeleton structures influencing the polarization and motility of cells \[[@B17-ijms-21-04852],[@B54-ijms-21-04852]\].

The WNT/Ca^2+^-signaling pathway is associated with the release of Ca^2+^ from intracellular stores. Interaction of WNT ligands with FZD activates phospholipase C (PLC) that hydrolyzes phosphatidylinositol (4,5)-biphosphates (PIP2) to inositol (1,4,5)-triphosphates (IP3) and diacylglycerol (DAG). DAG activates PKC kinase that in turn activates the small GTPase CDC42, while IP3 induces the release of Ca^2+^ ions from intracellular depots. Release of Ca^2+^ activates Ca^2+^/calmodulin dependent kinase II (CaMKII) and calcineurin (CaN). CaMKII phosphorylates TGFβ-activated kinase 1 (TAK1), which induces Nemo-like kinase (NLK) activation, which in turn inhibits transcriptional activity of canonical WNT-signaling. CaN via dephosphorylation activates nuclear factor of activated T-cells (NFAT) that translocates to the nucleus and regulates the expression of target genes. WNT/Ca^2+^ pathway activation plays an important role in the regulation of cell motility and cytoskeleton organization \[[@B17-ijms-21-04852],[@B54-ijms-21-04852],[@B55-ijms-21-04852]\].

2. WNT Signaling in Cancer {#sec2-ijms-21-04852}
==========================

As demonstrated in numerous studies, the aberrant activation of WNT-signaling contributes to malignant cell transformation and neoplastic proliferation with further metastatic dissemination and resistance to treatment \[[@B43-ijms-21-04852],[@B56-ijms-21-04852]\]. Many surface markers of cancer stem cells (CSCs) (CD44, CD24, CD133, LGR5/GPR49, ABC cassette genes, EpCAM) are direct targets of the WNT pathway. CSCs provide the long-term maintenance of the tumor and contribute to poor clinical outcome of therapies \[[@B43-ijms-21-04852]\]. Different genetic alterations can cause the inhibition of proteasomal degradation of β-catenin, resulting in the hyperactivation of canonical WNT-signaling and enhanced nuclear β-catenin accumulation. Genetic and epigenetic alterations affecting constituents of WNT pathways are tissue specific and they differ in frequency between cancers \[[@B56-ijms-21-04852]\]. Apart from the most frequent mutations of *APC* in colorectal cancer and *CTNNB1* in hepatocellular carcinoma, deregulations of several extracellular modulators of WNT-signaling e.g., DKKs, sFRPs and WIF1 also contribute to cancer development. These proteins antagonize canonical WNT-signaling by binding to LRP5/6 or inhibit the interaction between WNTs and their receptors \[[@B6-ijms-21-04852]\]. Moreover, vacuolar H^+^-ATPase (v-ATPase), an electrogenic H^+^ transporter required for WNT-signaling activation may also trigger abnormal WNT/β-catenin-signaling and contribute to WNT-signaling-dependent tumorigenesis. High expression of v-ATPase subunits has been observed in colorectal, prostate, breast, ovarian and pancreatic cancer cells \[[@B23-ijms-21-04852]\]. Furthermore, it has also been demonstrated that β-catenin modulates the cancer microenvironment, participating in creating the niche for cancer progression \[[@B57-ijms-21-04852]\]. The pre-metastatic niche permits both the implantation of tumor cells into distant organs as well as their survival \[[@B58-ijms-21-04852],[@B59-ijms-21-04852],[@B60-ijms-21-04852],[@B61-ijms-21-04852]\]. However, high levels of nuclear β-catenin do not always indicate poor prognosis \[[@B57-ijms-21-04852]\]. For that reason, it is necessary to consider the cell type-specific background in order to assess and understand the cellular outcome of aberrations in WNT-signaling \[[@B62-ijms-21-04852]\].

3. WNT Signaling in Melanoma {#sec3-ijms-21-04852}
============================

3.1. Genetic and Epigenetic Alterations {#sec3dot1-ijms-21-04852}
---------------------------------------

Deregulations in the canonical WNT-signaling in cancer may result from diverse mutations and epigenetic mechanisms. Mutations in genes encoding distinct elements of the WNT pathway can cause (i) loss of function of the destruction complex, (ii) increase in nuclear localization of β-catenin resulting in β-catenin-mediated transactivation of several genes. Mutations are mostly detected in genes encoding components of the destruction complex such as *APC* and *AXIN*, but the gene encoding β-catenin, *CTNNB1*, is also frequently mutated in selected cancer types. High frequency of mutations causing hyperactivation of WNT-signaling can be detected for example in colorectal cancer \[[@B63-ijms-21-04852],[@B64-ijms-21-04852]\] and mutations in *APC* leading to APC loss of function have been found in about 70% of cases \[[@B65-ijms-21-04852],[@B66-ijms-21-04852],[@B67-ijms-21-04852]\].

In melanoma, frequencies of mutations in *APC*, *AXIN1* and *CTNNB1* are low, reaching according to cbioportal.org 10%, 2.9% and 5.9%, respectively ([Table 1](#ijms-21-04852-t001){ref-type="table"}), however, a significant interstudy variability exists. An early study reported mutations in *CTNNB1* in six of 26 melanoma cell lines, and all these mutations affect phosphorylation of β-catenin rending it resistant to proteasomal degradation \[[@B68-ijms-21-04852]\]. Several later studies have shown much lower frequencies of mutations in *CTNNB1* and *APC*, which put into question the importance of a genetic component in aberrant activity of β-catenin in melanoma \[[@B69-ijms-21-04852],[@B70-ijms-21-04852],[@B71-ijms-21-04852],[@B72-ijms-21-04852],[@B73-ijms-21-04852]\]. For example, only 1 of 65 primary melanomas harbored mutations of *CTNNB1*, and one third of cases showed nuclear accumulation of β-catenin \[[@B69-ijms-21-04852]\]. In another study, while a *CTNNB1* missense mutation and a truncating *APC* mutation were reported only in one out of forty cell lines, it has been demonstrated that hypermethylation of *APC* promoter was present in about 15% of melanoma biopsies and cell lines suggesting transcriptional silencing \[[@B74-ijms-21-04852]\]. This epigenetic regulation was, however, not accompanied with increased WNT-signaling probably due to residual activity of APC. Epigenetic regulation of WNT/β-catenin antagonists such as DKKs, WIF1 and sFRP2 contributes substantially to activation of β-catenin. *DKK1*, *DKK2* and *DKK3* downregulation has been observed in melanoma cell lines and tissue samples, however, in contrast to other cancer types promoter hypermethylation is responsible only for downregulation of *DKK2* \[[@B75-ijms-21-04852]\]. Promoter methylation of *WIF1* has been shown as leading to *WIF1* silencing \[[@B76-ijms-21-04852],[@B77-ijms-21-04852]\]. Luo et al. have found that methylation of the *sFRP2* promoter results in a significant decrease of sFRP2 in patient melanoma samples and melanoma cell lines compared with the paired adjacent non-tumor tissue and non-transformed melanocytes, respectively \[[@B78-ijms-21-04852]\].

3.2. Canonical Signaling {#sec3dot2-ijms-21-04852}
------------------------

WNT-signaling plays an important function in skin. WNT/β -catenin-signaling guides the migration of neural crest cells, multipotent precursor cells and drives them toward a melanocyte fate \[[@B82-ijms-21-04852],[@B83-ijms-21-04852],[@B84-ijms-21-04852]\], including terminal differentiation of melanoblasts to melanocytes \[[@B83-ijms-21-04852]\]. WNT/β-catenin-signaling is also responsible for the maintenance of homeostasis between melanocytes and keratinocytes in normal epidermis \[[@B44-ijms-21-04852],[@B54-ijms-21-04852]\]. The activation of MITF, a lineage-specific transcription factor, by the canonical WNT-signaling plays an important role in melanocytes \[[@B85-ijms-21-04852]\]. It has been observed that the fate of neural crest cells depends on MITF, as cells with low MITF level differentiate toward e.g., neurons, glial cells or cartilage, whereas cells with high MITF give rise to melanocytes \[[@B84-ijms-21-04852]\]. In the context of melanocyte lineage, β-catenin not only controls expression of *MITF*, but also modulates its function via direct protein--protein interaction \[[@B86-ijms-21-04852]\].

As melanoma cells utilize WNT/β-catenin-signaling for transformation and proliferation, whereas non-canonical signaling for metastasis \[[@B87-ijms-21-04852]\], β-catenin does not fully comply with the definition of an oncogene in this cancer \[[@B88-ijms-21-04852]\]. The exact role of WNT-signaling in melanoma initiation and progression remains highly controversial to date despite extensive studies. While an increasing level of nuclear β-catenin during cancer progression is characteristic for several cancer types including colorectal cancer and hepatocellular carcinoma \[[@B89-ijms-21-04852],[@B90-ijms-21-04852],[@B91-ijms-21-04852],[@B92-ijms-21-04852]\], the level of nuclear β-catenin is decreased in melanoma during disease progression \[[@B62-ijms-21-04852],[@B93-ijms-21-04852],[@B94-ijms-21-04852],[@B95-ijms-21-04852],[@B96-ijms-21-04852],[@B97-ijms-21-04852]\]. However, opposite results have been published as well \[[@B98-ijms-21-04852],[@B99-ijms-21-04852],[@B100-ijms-21-04852]\]. β-catenin hyperactivation in melanoma is rarely caused by mutations of *CTNNB1* \[[@B101-ijms-21-04852]\]. β-catenin has been shown to play a critical role in the early stages of melanocyte transformation \[[@B102-ijms-21-04852],[@B103-ijms-21-04852]\]. The initiation of melanoma includes enhanced proliferation of cells together with suppression of senescence leading to abnormal growth of melanocytes \[[@B104-ijms-21-04852]\]. Senescence is mediated by two main tumor suppressor pathways: INK4α/RB and ARF/p53 \[[@B105-ijms-21-04852]\]. The *INK4α-ARF* (CDKN2α) locus encodes two proteins: p16^INK4a^ and p14(p19)^ARF^, regulating RB1 and p53 pathways, respectively. Inactivation of the genetic locus *INK4α-ARF* is important in overcoming the senescence barrier to oncogenesis \[[@B104-ijms-21-04852]\]. In a variety of cancers, this locus is inactivated by mutations, whereas it has also been found that *p16^INK4a^* expression can be silenced by activated β-catenin \[[@B103-ijms-21-04852]\]. Delmas et al. observed the ability of β-catenin to bypass senescence by silencing the *p16^INK4a^* through a conserved TCF/LEF site in its promoter \[[@B103-ijms-21-04852]\]. Activation of β-catenin in melanoma is a consequence of binding of WNT1 and WNT3A to their receptors FZD1/7 and co-receptors LRP5/6 and ROR1. These two ligands are crucial for bypassing melanocyte senescence and inducing transformation of melanocytes \[[@B103-ijms-21-04852],[@B106-ijms-21-04852]\]. While benign nevi have been found to be positive for nuclear β-catenin, loss of nuclear β-catenin during melanoma progression to metastases has been reported \[[@B62-ijms-21-04852],[@B94-ijms-21-04852],[@B107-ijms-21-04852]\]. The importance of canonical WNT-signaling in melanoma initiation is mostly associated with β-catenin ability to regulate the expression of a wide range of genes of the melanocyte lineage, and its involvement in regulation of proliferation is most likely related to the activation of MITF expression \[[@B42-ijms-21-04852],[@B44-ijms-21-04852],[@B62-ijms-21-04852],[@B108-ijms-21-04852],[@B109-ijms-21-04852],[@B110-ijms-21-04852]\]. The rheostat model and phenotype switching model of MITF function in melanoma \[[@B111-ijms-21-04852],[@B112-ijms-21-04852],[@B113-ijms-21-04852]\] suggest that a very low MITF level or the absence of MITF results in cell senescence, a low level is characteristic for invasive/dedifferentiated melanoma cells, whereas a high level of MITF pushes cells first toward a highly proliferative phenotype and finally to differentiation. Therefore, MITF is considered to be a master regulator of 'phenotype switching' between proliferative and invasive states, contributing to the high plasticity of melanoma cells in response to changes in the tumor microenvironment, including response to treatment \[[@B82-ijms-21-04852],[@B114-ijms-21-04852],[@B115-ijms-21-04852],[@B116-ijms-21-04852],[@B117-ijms-21-04852]\]. Moreover, MITF plays an important pro-survival role in melanoma cells \[[@B118-ijms-21-04852]\]. Recently, a differentiation model of melanoma has been proposed, in which the level of MITF is one of crucial factors determining subtypes of melanoma exerting differential vulnerability to drug-induced stress \[[@B119-ijms-21-04852]\]. In view of the correlation between β-catenin and MITF expression, WNT-signaling also affects melanoma plasticity \[[@B120-ijms-21-04852]\]. In actively proliferating melanoma cells, nuclear β-catenin/LEF1 triggers the expression of MITF that in turn activates transcription of several genes, including genes encoding cell cycle regulators p16, p21 and cyclin dependent kinase 2 (CDK2, pigmentation-related proteins such tyrosinase, dopachrome tautomerase (DCT) and Melan-A and pro-survival factors e.g., BCL2 and BCL2A1 \[[@B42-ijms-21-04852],[@B118-ijms-21-04852],[@B121-ijms-21-04852]\]. Active β-catenin-signaling leads to increased differentiation in benign lesions \[[@B62-ijms-21-04852],[@B117-ijms-21-04852]\] as it disrupts the regulatory balance between PAX3, SOX10 and MITF towards terminal differentiation \[[@B83-ijms-21-04852]\]. It has been found that β-catenin mediates the activation of POU domain of transcription factor BRN2 that plays a complex role in regulation of MITF \[[@B83-ijms-21-04852],[@B101-ijms-21-04852]\]. BRN2 tends to be highly expressed in melanomas, which suggests that it can be a positive regulator of melanoma survival and proliferation \[[@B83-ijms-21-04852]\]. It has been reported that depending on the cellular context, BRN2 can transcribe or repress MITF. It can drive MITF-mediated proliferation in the presence of oncogenic BRAF, whereas in the absence of mutated BRAF it can represses MITF promoting invasion \[[@B101-ijms-21-04852]\]. Moreover, the proliferative MITF^high^ subpopulation of melanoma cells producing melanoma antigen recognized by T cells 1 (MART1) are less invasive, whereas when this differentiation antigen is lost melanoma cells acquire highly invasive properties \[[@B122-ijms-21-04852]\]. Differential behavior of β-catenin in epithelial cancers and melanoma is associated with opposing features of epithelial cells and melanocytes \[[@B99-ijms-21-04852]\]. Therefore, it has been strongly emphasized that these diverse effects of β-catenin in melanoma cells and epithelial-derived cancers may be connected with the activity of MITF \[[@B62-ijms-21-04852],[@B99-ijms-21-04852]\]. Arozarena et al. have shown the correlation between the expression of β-catenin and MITF both in cell lines and melanoma biopsies \[[@B62-ijms-21-04852]\]. When low β-catenin and highly invasive cells were treated with forskolin, an agent upregulating MITF, the complete loss of membrane blebs and F-actin cortex contraction was observed. In line with this, melanoma cells with high β-catenin and high MITF levels have been characterized with an elongated filopodia phenotype and MITF reduction significantly increased rounded blebbing cells \[[@B62-ijms-21-04852]\]. The round shape morphology is regulated by phosphorylation of RHO/ROCK-mediated myosin light chain (MLC) that induces the contraction of the cortical actin meshwork, regulating bleb retraction of cells.

Aberrant expression of WNT/β-catenin antagonists (e.g., DKKs, WIF1, sFRPs) is common in melanoma and is associated with elevated β-catenin level. Downregulation of DKKs has been detected in melanoma cell lines and tissue samples \[[@B75-ijms-21-04852]\]. Reduced level of WIF1 has been found to contribute to constitutive activation of canonical WNT-signaling in melanoma cells, and *WIF1* overexpression resulted in downregulation of WNT-signaling and suppression of melanoma cell proliferation \[[@B76-ijms-21-04852]\]. Differences in *WIF1* expression have been observed between its level in the primary tumor and sentinel lymph node (SLN) metastases \[[@B77-ijms-21-04852]\]. Similarly, decreased expression of sFRPs, leading to upregulated WNT/β-catenin-signaling is also common in melanoma, and sFRP1 has been shown as an appealing candidate for a tumor suppressor \[[@B123-ijms-21-04852]\]. Reduction of sFRP2 enhances the canonical WNT-signaling, whereas demethylation of its promoter inhibits the nuclear retention of β-catenin in melanoma cells and suppresses invasion \[[@B78-ijms-21-04852]\]. Kaur et al. have found that sFRP2 is expressed by aged fibroblasts that play an important role in melanoma progression and this expression is associated with melanoma metastasis, therapy resistance and poor outcomes in elderly patients \[[@B82-ijms-21-04852]\]. sFRP2 decreases β-catenin, MITF and apurinic/apyrimidinic endonuclease 1 (APE1). APE1 is the redox effector involved in DNA repair, so its decrease can attenuate the response of melanoma cells to DNA damage induced by reactive oxygen species, making melanoma cells more resistant to vemurafenib \[[@B82-ijms-21-04852]\].

3.3. Non-Canonical WNT Signaling {#sec3dot3-ijms-21-04852}
--------------------------------

Non-canonical WNT-signaling, which is activated during melanoma progression, suppresses the WNT/β-catenin-signaling \[[@B107-ijms-21-04852],[@B124-ijms-21-04852]\]. The interaction of canonical and non-canonical WNT-signaling in melanoma is presented in [Figure 3](#ijms-21-04852-f003){ref-type="fig"}. A lower level of nuclear β-catenin was detected in metastases than in primary melanoma in 343-melanoma samples \[[@B107-ijms-21-04852]\]. Immunohistochemical analyses have revealed that most metastatic melanoma exhibited strong WNT5A staining comparing to benign tumors and a high WNT5A level in metastatic cutaneous melanoma is associated with poor outcome \[[@B125-ijms-21-04852]\]. Therefore, it has been suggested that lack of nuclear β-catenin and high level of cytoplasmic WNT5A can be indicatives of unfavorable prognosis for melanoma patients \[[@B62-ijms-21-04852],[@B107-ijms-21-04852],[@B125-ijms-21-04852]\]. Furthermore, inducible overexpression of WNT5A in melanoma cells exhibiting low metastatic activity results in enhanced invasiveness \[[@B126-ijms-21-04852]\], whereas siRNA-mediated knockdown of ROR2, the WNT5A receptor, reduced the frequency and severity of lung metastases in mice \[[@B127-ijms-21-04852]\]. Pro-metastatic effects of WNT5A have been associated with aerobic glycolysis promoted by WNT5A in melanoma cells \[[@B128-ijms-21-04852]\]. WNT5A-mediated Ca^2+^-dependent release of exosomes by melanoma cells has been reported \[[@B129-ijms-21-04852]\]. Exosomes are the smallest type of extracellular vesicles (30--180 nm in diameter), whose role in melanoma has been extensively discussed recently \[[@B61-ijms-21-04852]\]. Using recombinant WNT5A in melanoma cells expressing low endogenous WNT5A induces a rapid release of exosomes containing the immunomodulatory cytokine interleukin 6 (IL-6) and the pro-angiogenic factors interleukin 8 (IL-8), VEGF and matrix metalloproteinase-2 (MMP2), whereas WNT5A depletion in melanoma cells expressing high endogenous WNT5A causes the reduction of IL-6, IL-8, VEGF and MMP2. Release of immunomodulatory and pro-angiogenic molecules enhances aggressiveness of melanoma cells and their capacity to metastasize \[[@B129-ijms-21-04852]\]. Furthermore, it has been reported that WNT5A increases autophagy, which mediates resistance to various anticancer drugs. Knocking down autophagy-related gene 5 (ATG5) in WNT5A^high^ melanoma cells caused a reduction of the WNT5A level and induction of β-catenin \[[@B130-ijms-21-04852]\].

WNT5A can either inhibit or activate canonical WNT-signaling in diverse ways depending on the receptor context \[[@B131-ijms-21-04852]\]. Several of these mechanisms have been investigated in melanoma and the results revealed that WNT5A exerts a dichotomous role in melanoma ([Figure 3](#ijms-21-04852-f003){ref-type="fig"}). It can either stabilize β-catenin via adenosine diphosphate (ADP)-ribosylation factor 6 (ARF6) or suppress the WNT/β-catenin-signaling either by binding to FZD receptors or in a seven in absentia homolog 2 (SIAH2)-dependent manner. Binding of WNT5A to FZD4/LRP6 receptor complex activates ARF6 that in turn releases β-catenin from N-cadherin, which stimulates the shuttling of β-catenin between the membrane, cytoplasm and nucleus and enhances β-catenin-dependent transcription \[[@B132-ijms-21-04852]\]. WNT5A that signals through FXD2, FZD5 and ROR2 activates PKC/Ca^2+^-signaling \[[@B87-ijms-21-04852]\]. Calpain-1 (CAPN) mediates the cleavage of filamin A, promoting the remodeling of cytoskeleton and enhancing the motility of melanoma cells, whereas CAMKII inhibits β-catenin activity \[[@B87-ijms-21-04852]\]. PKC activates signal transducer and activator of transcription 3 (STAT3) leading to inhibition of MITF expression with concomitant downregulation of melanocytic differentiation antigens (Melan A (MART1), DCT and gp100), thus promoting the metastatic phenotype \[[@B87-ijms-21-04852]\]. Furthermore, PKC influences the motility of melanoma cells through the inhibition of metastasis repressor KISS-1 and E-cadherin and upregulation of metastasis-associated molecules, CD44 and SNAIL, resulting in transition to an invasive phenotype \[[@B87-ijms-21-04852],[@B133-ijms-21-04852]\]. WNT5A can compete with WNT3A for binding to FZD2, and in this way LPR6 phosphorylation and β-catenin accumulation can be inhibited \[[@B122-ijms-21-04852],[@B134-ijms-21-04852]\].

WNT5A can act through SIAH2 via the GSK3-β-independent pathway to promote degradation of β-catenin \[[@B135-ijms-21-04852],[@B136-ijms-21-04852],[@B137-ijms-21-04852]\]. This mechanism of switching from WNT/β-catenin-signaling to non-canonical WNT-signaling has been associated with resistance to targeted therapy \[[@B136-ijms-21-04852]\]. A high level of WNT5A promotes the resistance to vemurafenib, highlighting the opposing roles of different WNT pathways in melanoma \[[@B87-ijms-21-04852]\]. Melanoma cells exerting a high level of WNT5A when exposed to vemurafenib treatment or other stress, developed a sort of drug resistant state (pseudosenescence), still retaining invasive capacity and the ability to form metastases. Furthermore, the pseudosenescent WNT5A-high cells were capable to express factors similar to those secreted by senescent fibroblasts and were positive for senescence markers, e.g., β-galactosidase, Src homology 2 domain containing F (SHF) and methylated of histone H3 on lysine 9 (H3K9Me). This WNT5A-mediated senescence-like response may be the mechanism that allows the tumor to evade therapy by undergoing growth arrest \[[@B122-ijms-21-04852]\].

FZD3 has been found to be associated with β-catenin-independent-signaling and upregulation of this receptor is associated with melanoma progression and a reduced patient survival, whereas down-regulation of FZD3 suppresses growth and metastasis of melanoma \[[@B138-ijms-21-04852]\]. Overexpressed FZD3 has been detected in 20% of melanoma patients whose tumors were deprived of infiltrating T cells indicating the importance of this receptor in immune evasion \[[@B139-ijms-21-04852]\]. Moreover, it has been observed that FZD3 effectively modulates the activity of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway that is critical for melanoma maintenance. Therefore, FZD3 blocking agents may enhance the efficacy of melanoma treatment when used in combination with available kinase inhibitors and immunotherapy \[[@B138-ijms-21-04852],[@B139-ijms-21-04852]\].

4. Crosstalk between WNT Signaling and Key Oncogenic Pathways Involved in Melanoma Development, Progression and Response to Treatment {#sec4-ijms-21-04852}
=====================================================================================================================================

The complex interactions existing between diverse signaling pathways create the opportunity for a cancer cell to compensate for a blockade of a single pathway. The crosstalk consisting of multiple interactions and feedback loops is crucial for the cellular response to microenvironmental changes, including treatment. WNT-signaling is an important part of the crosstalk between key oncogenic pathways involved in melanoma development, progression and response to treatment. Elements of the WNT-signaling pathways both depend on and regulate activities of diverse pathways such as MAPK/ERK and phosphatidylinositol-3-kinase (PI3K)/AKT as well as transcriptional regulators including p53 and MITF. [Figure 4](#ijms-21-04852-f004){ref-type="fig"} shows main signal transduction pathways and transcriptional regulators that interact with the WNT-signaling pathways in melanoma.

WNT-signaling can interact with MAPK/ERK and PI3K/AKT-signaling in diverse ways. Moreover, growing evidence indicates that this crosstalk in melanoma depends on the genetic context and several mechanisms are considered as tumor stage-dependent or unique for melanoma. In an early study, it was shown that WNT/β-catenin and MAPK/ERK pathways synergized in order to induce melanoma without the need for p16INK4a mutations and β-catenin could cooperate with N-RAS \[[@B103-ijms-21-04852]\]. Next, it was found that inhibition of BRAF^V600^ enhanced the activity of β-catenin in the presence of WNT ligands \[[@B140-ijms-21-04852]\]. This combination of BRAF inhibition and WNT/β-catenin activation was accompanied by AXIN1 degradation and inhibition of GSK3β, whereas hyperactivated MAPK/ERK-signaling stabilized AXIN1 that inhibited WNT-signaling in melanoma \[[@B140-ijms-21-04852]\]. This negative crosstalk between MAPK/ERK and WNT/β-catenin-signaling was considered as melanoma specific since in colon cancer and many other cancers, activation of WNT/β-catenin-signaling leads to the stabilization of both β-catenin and RAS and activation of MAPK-signaling \[[@B141-ijms-21-04852],[@B142-ijms-21-04852]\]. In another study performed in a mouse model of melanoma and human biopsies, β-catenin stabilization was associated with increased activation of MAPK/ERK and PI3K/AKT-signaling in BRAF activated and PTEN inactivated highly metastatic melanomas \[[@B98-ijms-21-04852]\]. Full activation of AKT was detected, however, only in a small subset of melanomas \[[@B98-ijms-21-04852]\]. These results suggest that the crosstalk between MAPK/ERK, PI3K/AKT and WNT/β-catenin-signaling depends on the genetic context. When phenotypic effects of the WNT/β-catenin pathway were compared in wild-type and mutated PTEN melanomas, the invasiveness and bioenergetics of melanoma cells were found to be regulated by WNT3A/β-catenin in a PTEN-dependent manner \[[@B57-ijms-21-04852]\]. A most recent report has demonstrated that there is a high variability in the activity of PI3K/AKT and WNT/β-catenin pathways in melanomas with BRAF^V600E^ and wild-type PTEN \[[@B143-ijms-21-04852]\]. Moreover, the activity of these pathways can be largely modified in the response to targeted therapeutics and after the development of drug resistance \[[@B140-ijms-21-04852],[@B143-ijms-21-04852],[@B144-ijms-21-04852]\]. Nuclear localization of β-catenin can be increased by prostaglandins, which indicates the potential crosstalk between WNT-signaling and the cyclooxygenase 2 (COX-2)/prostaglandin pathway \[[@B145-ijms-21-04852]\]. COX-2 is a target gene of β-catenin transcription, and in addition, β-catenin contributes to the stabilization of COX-2 mRNA \[[@B145-ijms-21-04852]\].

Transcription factors responding to diverse signal transduction pathways play a key role in integrating multiple signals to give rise to the optimal phenotype confronting the cancer developmental stage and microenvironmental insults \[[@B85-ijms-21-04852]\]. MITF, a melanocyte and melanoma specific transcription factor is under control of many signaling pathways and active β-catenin contributes to its transcription \[[@B85-ijms-21-04852]\]. MAPK/ERK, PI3K/AKT and WNT/β-catenin-signaling pathways are also able to post-translationally modify MITF \[[@B115-ijms-21-04852]\]. ERK-mediated phosphorylation of MITF results in increased binding of p300/CBP \[[@B146-ijms-21-04852]\] as well as proteasomal degradation \[[@B147-ijms-21-04852],[@B148-ijms-21-04852]\]. It is worth to note that WNT/β-catenin, MAPK/ERK and PI3K/AKT-signaling can converge to regulate nuclear transport of MITF \[[@B149-ijms-21-04852]\]. Phosphorylation of MITF by ERK1/2 primes MITF for phosphorylation by GSK3β \[[@B149-ijms-21-04852]\], a kinase that is inhibited by both PI3K/AKT and WNT/β-catenin-signaling. This dual phosphorylation is an example how multiple signaling pathways can converge to control the activity of a specific transcription factor. MITF activity is also dependent on the non-canonical WNT pathway as PKC can activate STAT3 leading to inhibition of MITF expression with concomitant downregulation of melanocytic differentiation antigens (Melan A (MART1), DCT and gp100), thus promoting the metastatic phenotype \[[@B87-ijms-21-04852],[@B101-ijms-21-04852]\].

The WNT5A impact on p53 activity is another example of the influence of non-canonical WNT-signaling on the transcription factor-mediated phenotype of melanoma cells. As shown most recently, a high expression of WNT5A is observed in wild-type p53 melanomas representing 80% of this cancer, and more important, WNT5A can promote a slow-cycling phenotype of melanoma cells by increasing the half-life of wild-type p53 \[[@B150-ijms-21-04852]\]. WNT5A expression can be enhanced by aging or treatment of melanoma with targeted therapy or irradiation \[[@B82-ijms-21-04852],[@B121-ijms-21-04852],[@B151-ijms-21-04852]\]. Following different types of stress, a slow-cycling phenotype is induced, which in turn may promote melanoma survival, plasticity and heterogeneity. However, WNT5A can stabilize p53, p53-induced apoptosis is inhibited, and melanoma cells are arrested. As p53 has been shown to inhibit WNT-signaling \[[@B152-ijms-21-04852],[@B153-ijms-21-04852],[@B154-ijms-21-04852]\], a feedback loop WNT-p53-WNT that is possible in wild type p53 melanomas has been suggested \[[@B150-ijms-21-04852]\]. A possible explanation is that PKC activated by WNT5A phosphorylates the inhibitor of apoptosis stimulating protein (iASPP) leading to its nuclear localization, which prevents p53-induced apoptosis \[[@B133-ijms-21-04852],[@B155-ijms-21-04852]\]. As SIAH2 is a target of p53 \[[@B156-ijms-21-04852],[@B157-ijms-21-04852]\], WNT5A-stabilized p53 may in turn increase SIAH2 expression and β-catenin degradation in melanoma \[[@B150-ijms-21-04852]\]. Most recently, it has been shown that β-catenin can be a direct partner of SOX10 via protein--protein interactions, which reduces SOX10 protein level in melanoma cells \[[@B158-ijms-21-04852]\]. These results suggest that SOX10 considered as functionally crucial for melanoma survival can be suppressed by WNT/β-catenin-signaling. Of note, SOX10 level has not been reduced by main targeted therapeutics used in melanoma treatment \[[@B117-ijms-21-04852],[@B158-ijms-21-04852]\], and in selected vemurafenib- or trametinib-resistant melanoma cell lines has been even increased \[[@B143-ijms-21-04852]\]. Interestingly, SOX10 expression in hepatocellular carcinoma has been shown to correlate with enhanced level of β-catenin, and active β-catenin forming a stable SOX10/TCF4/β-catenin complex is necessary for the oncogenic effects of SOX10 \[[@B159-ijms-21-04852]\]. These examples illustrate how direct and indirect interactions of WNT-signaling with transcription factors can influence the melanoma cell phenotype.

5. WNT-Signaling in Cancer Immunity {#sec5-ijms-21-04852}
===================================

Various studies indicate that WNT-signaling is associated with several aspects of immunity, and alterations in WNT-signaling can be connected with the deregulation of immune response against cancer, both innate and adaptive \[[@B56-ijms-21-04852],[@B160-ijms-21-04852],[@B161-ijms-21-04852],[@B162-ijms-21-04852],[@B163-ijms-21-04852],[@B164-ijms-21-04852],[@B165-ijms-21-04852],[@B166-ijms-21-04852],[@B167-ijms-21-04852]\]. Tumors can be classified as having or lacking a T-cell-inflamed microenvironment \[[@B168-ijms-21-04852]\] and immunotherapeutic interventions, including checkpoint inhibitors such as antiprogrammed death 1 (PD-1), programmed death-ligand 1 (PD-L1) and anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibodies have shown efficacy in patients with a preexisting T cell-inflamed cancer microenvironment \[[@B169-ijms-21-04852]\]. Therefore, understanding the mechanisms underlying T cell exclusion is of clinical relevance. Most recently performed analysis of tumor microenvironment has revealed that about one-third of solid tumors have poor T cell infiltration, and tumor-intrinsic WNT/β-catenin-signaling inversely correlates with a T cell-inflamed phenotype in 90% of tumor types \[[@B170-ijms-21-04852]\]. Authors suggest that activation of WNT/β-catenin in tumor cells is one of the possible mechanisms of intrinsic resistance to immunotherapy. The link between the WNT/β-catenin pathway and immune exclusion has been first identified in melanoma \[[@B171-ijms-21-04852],[@B172-ijms-21-04852]\]. Gene expression profiling and exome sequencing of 266 individual melanoma metastases has revealed that about 48% of the non-inflamed melanomas exert active WNT/β-catenin pathway with elevated expression of genes under control of this signaling \[[@B171-ijms-21-04852]\]. Mutations potentially leading to the WNT/β-catenin pathway activation, either gain-of-function mutations in *CTNNB1* (8%) or loss of function mutations (11%) in genes encoding negative regulators of WNT/β-catenin-signaling have been detected in these metastases \[[@B171-ijms-21-04852]\]. Genetically engineered mouse models expressing conditionally active β-catenin have been used to show that melanomas with enhanced activation of WNT/β-catenin lack T cell infiltrate, which is due to insufficient recruitment of CD103/CD8α dendritic cells (DCs) \[[@B172-ijms-21-04852]\]. This escape of immunity developed after activation of WNT-signaling in melanoma cells is accompanied by reduced secretion of CC-motif chemokine ligand 4 (CCL4), a chemokine that attracts the immune cells ([Figure 5](#ijms-21-04852-f005){ref-type="fig"}). The CCL4 expression is downregulated by β-catenin via activating transcription factor 3 (ATF3) \[[@B172-ijms-21-04852]\]. Interestingly, no therapeutic effect of anti-CTLA-4 and anti-PD-L1 was observed in mice with melanoma expressing active β-catenin unless DCs were injected to activate tumor antigen-specific T cells. As immune evasion mediated by WNT/β-catenin-signaling frequently operates already in primary melanomas, it has been suggested that β-catenin-based stratification of patients may improve immunotherapeutic outcomes \[[@B173-ijms-21-04852]\].

As activation of tumor-intrinsic WNT/β-catenin-signaling is enhanced in non-T cell-inflamed tumors, the WNT-signaling inhibitors may be useful for restoring immune cell infiltration to support immunotherapy.

6. WNT-Targeted Therapies {#sec6-ijms-21-04852}
=========================

The important role of WNT-signaling in the development and adult life as well as its implication in a wide spectrum of diseases, including cancer has already attracted the attention of medical and biotech companies. Ongoing research is focused on the development of specific inhibitors of WNT/β-catenin-signaling for cancer therapies, and only very few modulators of non-canonical signaling are known. Based on the recent advances in cancer biology, targeting of WNT-signaling in cancer cells has to be put into perspective of its effectiveness either in reversing resistance to anticancer drugs or in inhibition of tumor evasion. It is important to underline that it is difficult to target only the WNT pathway without interfering with other signaling pathways. Diverse compounds of natural origin or synthetic, peptides and antibodies that are in preclinical studies are shown in [Table 2](#ijms-21-04852-t002){ref-type="table"}. Natural compounds targeting WNT-signaling have been discussed extensively \[[@B174-ijms-21-04852],[@B175-ijms-21-04852]\], and therefore only few of them are included in [Table 2](#ijms-21-04852-t002){ref-type="table"}.

Several agents influencing WNT-signaling have reached the clinical trials ([Table 3](#ijms-21-04852-t003){ref-type="table"}). Many of these inhibitors cause, however, severe side effects associated with impairment of tissue homeostasis and tissue regeneration, and off-target effects of WNT inhibitor are still an unresolved problem. Most of the clinical trials are conducted with patients with colorectal cancer ([Table 3](#ijms-21-04852-t003){ref-type="table"}), and so far, melanoma patients were included only in one clinical trial (NCT01351103).

As shown in [Table 2](#ijms-21-04852-t002){ref-type="table"} and [Table 3](#ijms-21-04852-t003){ref-type="table"}, WNT pathways can be affected by drugs at various stages. The first stage, WNT ligand activation and binding, is the most intensively investigated part of the WNT/β-catenin pathway. Porcupine, an enzyme with the acyl-transferase activity necessary for palmitoylation of WNT ligands, was one of the first targets \[[@B6-ijms-21-04852],[@B8-ijms-21-04852],[@B14-ijms-21-04852]\]. The porcupine inhibitor WNT974 (also known as LGK974) is under clinical evaluation in several cancer types, including melanoma (NCT01351103) \[[@B184-ijms-21-04852],[@B185-ijms-21-04852]\] ([Table 3](#ijms-21-04852-t003){ref-type="table"}). C59 is another porcupine inhibitor investigated in melanoma that diminished WNT/β-catenin-signaling. It synergizes with anti-CLA-4 antibody in the B16 melanoma model, suggesting a synergistic enhancement in antitumor immunity \[[@B176-ijms-21-04852]\]. A monoclonal antibody (WNT-2Ab) against human WNT2 ligand has been developed to induce apoptosis in melanoma cells exerting WNT2 overexpression, and WNT-2Ab treatment downregulated β-catenin target genes, e.g., CCND1 and c-Myc \[[@B177-ijms-21-04852]\]. Phase 1 clinical trial for Foxy-5 (formylated 6-amino-acid peptide fragment), a WNT5A-mimicking peptide has already been completed in colorectal cancer and has shown a promising therapeutic value \[[@B191-ijms-21-04852],[@B192-ijms-21-04852]\]. FZD receptors are potential targets of WNT directed therapies. The attenuation of WNT-signaling can be achieved by ubiquitylation-mediated degradation of FZD by anti-RSPO3 mAb (OMP-131R10). Phase 1 clinical trial employing OMP-131R10 has been completed with colorectal cancer patients \[[@B193-ijms-21-04852]\]. OMP-18R5 (Vantictumab), a human monoclonal antibody has been used to inhibit ligand binding by targeting FZD receptors (FZD 1, 2, 5, 7, 8) \[[@B190-ijms-21-04852]\]. The activity of OMP-54F28 (Ipafricept, completed phase I clinical trial) is based on the competition with FZD8 for ligand binding. OMP-54F28 is a recombinant fusion protein that consists of cysteine-rich domain of FZD8 and Fc domain of immunoglobulin and it functions as a trap for FZD8-binding of WNTs \[[@B189-ijms-21-04852],[@B206-ijms-21-04852]\]. FZD can also be targeted by niclosamide, a plant derived compound that is capable of inducing FZD1 internalization and DVL down-regulation \[[@B194-ijms-21-04852],[@B207-ijms-21-04852]\]. It downregulates B-cell lymphoma 9 (BCL9) that impairs the formation of active β-catenin/TCF/LEF triple-complex and upregulates c-JUN \[[@B200-ijms-21-04852]\]. Niclosamide has already entered clinical trials in colorectal cancer. Poor systemic bioavailability of niclosamide led to the development of pro-drugs with better pharmacokinetic properties \[[@B208-ijms-21-04852]\]. DKK1 inhibitors also belong to molecules targeting WNT-signaling, as DKK1, initially characterized as tumor suppressor may also function as tumor promoter \[[@B209-ijms-21-04852]\]. DKN-01, a humanized monoclonal neutralizing antibody against DKK1 recognized as having potential therapeutic implications \[[@B210-ijms-21-04852]\], has entered clinical trials. There are also WNT-signaling inhibitors that target FZD-DVL interaction e.g., FJ9 that disrupts the interaction between FZD7 and DVL. FJ9 has been found to downregulate canonical WNT-signaling and induce apoptosis in lung cancer and melanoma cells \[[@B178-ijms-21-04852]\]. Another group of inhibitors belongs to intracellular drugs targeting the destruction complex. Tankyrases are the enzymes that degrade AXIN1 and AXIN2 through poly ADP-ribosylation. A very recent report indicates that inhibition of tankyrase by G007-LK can be used to overcome WNT/β-catenin-mediated resistance to immune checkpoint inhibitors \[[@B179-ijms-21-04852]\]. While previously used tankyrase inhibitors caused bone loss \[[@B211-ijms-21-04852]\] and intestinal toxicity \[[@B212-ijms-21-04852]\], no such signs were observed in mice treated with G007-LK \[[@B179-ijms-21-04852]\]. Growing evidence indicates that dietary factors along with alteration in the gutactivator protein 1 microbiota can affect WNT-signaling. Genistein, a soy-derived isoflavone, for which clinical trial phase 1 and 2 has been completed in CRC, inactivates WNT-signaling by GSK3-β targeting \[[@B202-ijms-21-04852],[@B203-ijms-21-04852],[@B213-ijms-21-04852]\]. Fisetin (3,7,3′,4′-tetrahydroxyflavone) is a dietary flavonoid that inhibits GSK3-β and activates β-catenin in melanoma cells \[[@B180-ijms-21-04852]\]. Another plant-derived molecule known to modulate WNT-signaling in melanoma is a triterpene lupeol, (lup-20(29)-en-3β-ol). It has been found that lupeol prevented the translocation of β-catenin to the nucleus, therefore decreased nuclear β-catenin level and expression of β-catenin target genes e.g., coding region determinant-binding protein (*CRD-BP*), *MITF* and *CCND1* \[[@B182-ijms-21-04852]\]. Pentoxifylline, a drug approved by the FDA for the treatment of peripheral arterial disease, markedly reduced the level of active β-catenin in the nucleus of melanoma cells with high basal expression of β-catenin \[[@B183-ijms-21-04852]\].

As demonstrated above, there is a large group of natural or synthetic compounds, peptides and antibodies that are capable of affecting, either inducing or inhibiting, the WNT-signaling pathways at various stages. Compounds that have been investigated in melanoma are shown in [Figure 6](#ijms-21-04852-f006){ref-type="fig"}.

While inhibition of WNT-signaling represents an immensely appealing strategy for the development of anticancer therapeutics, none of drugs targeting WNT-signaling is yet available in clinical practice \[[@B4-ijms-21-04852],[@B214-ijms-21-04852]\].

7. Conclusions {#sec7-ijms-21-04852}
==============

WNT-signaling is extremely complex and context-dependent in cancer, including melanoma. Deregulation of WNT-signaling contributes to cancer initiation, progression, modulation of immune microenvironment and resistance to treatment. While WNT-signaling alterations start with *APC* mutations in about 70% of colorectal cancer patients, mutations are not the major cause of these deregulations in melanoma. Moreover, transcriptionally active β-catenin is associated with less invasive disease and more favorable prognosis for melanoma patients, in contrast to other cancers, in which nuclear β-catenin is a driving force of both initiation and progression. It is thought that β-catenin-suppressed invasion occurs through a cell-type specific mechanism involving transcription factor MITF, one of the β-catenin target genes. On the other hand, low efficacy of immunotherapy is observed in melanomas with elevated level of β-catenin. The identification of therapeutic targets is further complicated by the crosstalk between WNT-signaling pathways and other signaling pathways crucial for melanoma development such as MAPK/ERK and PI3K/AKT, as well as the plasticity of melanoma cells in response to microenvironmental insults. Therefore, finding a therapeutic window for effective modulation of the WNT pathway in melanoma is a challenging task. A low number of clinical trials investigating WNT/β-catenin modulators in melanoma patients is the consequence of the controversial role of WNT-signaling in melanoma.
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seven in absentia homolog 2

SLN

sentinel lymph node

SMAD

mothers against decapentaplegic homolog

SRY

sex-determining region Y

STAT3

Signal Transducer Moreover, Activator Of Transcription 3.

SWI/SNF

SWItch/Sucrose non-fermentable chromatin-remodeling complex

TAK1

TGFβ-activated kinase 1

TCF/LEF

T cell factor/lymphoid enhancer-binding factor 1

TGF-β

transforming growth factor-β

v-ATPase

vacuolar H

\+

-Adenosine Triphosphatase.

VEGF

vascular endothelial growth factor

WIF1

WNT inhibitory factor 1

WISE

WNT modulator in surface ectoderm

WISP1

WNT1-inducible-signaling pathway protein 1

ZNRF3

zinc and ring finger protein 3

![Simplified scheme of canonical WNT -signaling pathway. (**A**) In the absence of WNT ligands (WNT OFF state), β-catenin is phosphorylated by a destruction complex consisting of AXIN, APC, GSK3β and CK1α to be further ubiquitinated for proteasomal degradation. In the absence of R-spondins, E3 ubiquitin ligases RNF43/ZNRF3 target FZD for lysosomal degradation; (**B**) binding of WNT ligands to FZD receptors and LRP co-receptors activates WNT-signaling (WNT ON state). AXIN is associated with LRP5/6, whereas DVL is recruited to FZD, which results in dissociation of the destructive complex. β-catenin is accumulated and stabilized in the cytosol, and then unphosphorylated β-catenin is translocated to the nucleus to activate the expression of WNT target genes. APC---adenomatosis polyposis coli; AXIN---axis inhibition protein; BCL---B-cell CLL/lymphoma protein; BRG-1---brahma-related gene-1; CBP---(CREB)-binding protein; CK1α---casein kinase 1α; CK1γ---casein kinase 1γ; CK1ε---casein kinase 1ε; DKK1---Dickkopf-1; DVL---disheveled; FZD---frizzled receptor; GSK3β---glycogen synthase kinase 3β; LEF---lymphoid enhancer-binding factor 1; LGR---leucine-rich repeat-containing G-protein coupled receptor; LRP---low-density lipoprotein receptor related protein; MAK---metastasis associated kinase; PAR1---protease-activated receptor 1; PKC---protein kinase C; PYGO---pygopus; RNF43---ring finger protein 43; sFRP---secreted frizzled-related proteins; TCF---T cell factor; β-TrCP---beta-transducin repeats-containing proteins; WIF1---WNT inhibitory factor 1; WISE---WNT modulator in surface ectoderm; Ub; ubiquitin; ZNRF3---zinc and ring finger protein 3.](ijms-21-04852-g001){#ijms-21-04852-f001}

![An overview of non-canonical WNT-signaling pathways: (**A**) WNT/planar cell polarity-signaling pathway (PCP) is initiated by WNT binding to FZD and ROR, then DVL is recruited and DVL-Daam-1 complex is activated, followed by JNK and ROCK activation and cytoskeletal rearrangement; (**B**) WNT/Ca^2+^-signaling pathway is initiated by WNT binding to FZD and ROR, with further G-protein triggered phospholipase C activation leading to phospholipase C intracellular calcium fluxes and downstream calcium dependent responses. AP-1---activator protein 1; CaMKII---Ca2+/calmodulin dependent kinase II; CaN---calcineurin; CDC42---cell division cycle 42; DAG---diacylglycerol; DAAM1---DVL associated activator of morphogenesis; DVL---disheveled; FZD---frizzled; JNK---c-Jun N-terminal kinases; NLK---nemo like kinase; NFAT---nuclear factor of activated T-cells; PIP2---phosphatidylinositol (4,5)-biphosphates; PKC---protein kinase C; PLC---phospholipase C; RAC---Ras-related C3 botulinum toxin substrate; RHO---Ras homolog gene family; ROCK---Rho-associated kinase; ROR---RAR-related orphan receptor; TAK1---transforming growth factor beta-activated kinase 1.](ijms-21-04852-g002){#ijms-21-04852-f002}

![Proposed model of the crosstalk between canonical and non-canonical WNT-signaling in melanoma. In the canonical WNT pathway, WNT--FZD/LRP5/6 interaction initiates β-catenin dependent signaling. β-catenin translocates to the nucleus to drive the transcription of target genes. This is critical for early steps of transformation when melanocytes bypass senescence and start to proliferate, thus promoting first the radial then vertical growth of melanoma. An increase of WNT5A that activates non-canonical WNT-signaling inhibits β-catenin-signaling and enhances the invasiveness of melanoma cells crucial for metastatic spreading of melanoma. Green and red arrows indicate increase and decrease, respectively.](ijms-21-04852-g003){#ijms-21-04852-f003}

![Main signal transduction pathways and transcriptional regulators that interact with the WNT-signaling pathways in melanoma. Figure shows the possible crosstalk between different pathways, however, some of the interactions are genetic context-, disease stage- or treatment-dependent. See the text for more details. APC---adenomatosis polyposis coli; AXIN---axis inhibition protein; BCL---B-cell CLL/lymphoma protein; BRG-1---brahma-related gene-1; CBP---(CREB)-binding protein; CK1α---casein kinase 1α; COX-2---cyclooxygenase 2; DVL---disheveled; FZD---frizzled receptor; GSK3β---glycogen synthase kinase 3β; iASPP---inhibitor of apoptosis-stimulating protein of p53; LEF---lymphoid enhancer-binding factor 1; LRP---low-density lipoprotein receptor related protein; MITF---microphthalmia-associated transcription factor; PTEN---phosphatase and tensin homolog deleted on chromosome ten; PYGO---pygopus; mTOR---mammalian target of rapamycin; PI3K---phosphatidylinositol-3-kinase; RAS---Rat sarcoma.; ROR---RAR-related orphan receptor; RTK---receptor tyrosine kinase---SIAH2---seven in absentia homolog 2.](ijms-21-04852-g004){#ijms-21-04852-f004}

![Mechanisms of immune exclusion in melanoma through WNT/β-catenin-signaling \[[@B172-ijms-21-04852]\]. β-catenin induces expression of *ATF3* and ATF3 represses transcription of *CCL4*. CD103^+^ dendritic cells and cytotoxic CD8^+^ T-cells are not recruited to melanoma, which leads to non-inflamed tumor. When β-catenin-signaling is inactive in melanoma cells, *ATF3* is not expressed, which restores CCL4 production and secretion. This stimulates recruitment of immune cells, including CD103^+^ dendritic cells that activate CD8^+^ T cells. Recruitment of tumor specific CD8^+^ T cells in the tumor microenvironment results in immune inflamed melanoma. ATF3---activating transcription factor 3; β- cat---β- catenin; CCL4---CC-motif chemokine ligand 4.](ijms-21-04852-g005){#ijms-21-04852-f005}

![Compounds and antibodies affecting WNT/β-catenin-signaling pathway that were investigated in melanoma (preclinical studies, except for LGK974, which is tested in the clinical trial NCT01351103). APC---adenomatosis polyposis coli; AXIN---axis inhibition protein; BRG-1---brahma-related gene-1; BCL-9---B-cell CLL/lymphoma 9 protein; CBP---cAMP response element-binding protein; CK1α---casein kinase 1 α; CK1γ---casein kinase 1 γ; DKK1---Dickkopf-1; DVL---disheveled; ER---endoplasmic reticulum; FZD---frizzled; GSK3β---glycogen synthase kinase 3β; LRP5/6---lipoprotein receptor related protein 5/6; PYGO---pygopus; TKNS---tankyrase; β-TrCP---beta-transducin repeat--containing protein; Ub---ubiquitin.](ijms-21-04852-g006){#ijms-21-04852-f006}

ijms-21-04852-t001_Table 1

###### 

Frequency of mutations of genes encoding elements of the canonical WNT-signaling pathway detected in melanoma.

  ----------------------------------------------------------------------------
  Gene       Literature Data            Melanoma\                      
                                        (cbioportal.org; 1284 Cases)   
  ---------- -------------------------- ------------------------------ -------
  *APC*      15%                        \[[@B74-ijms-21-04852]\]       10.0%

  11%        \[[@B79-ijms-21-04852]\]                                  

  2.7%       \[[@B73-ijms-21-04852]\]                                  

  *AXIN1*    --                         2.9%                           

  *AXIN2*    11%                        \[[@B79-ijms-21-04852]\]       1.3%

  *BCL9*     --                         5.7%                           

  *CTNNB1*   23%                        \[[@B68-ijms-21-04852]\]       5.9%

  4.6%       \[[@B71-ijms-21-04852]\]                                  

  3.3%       \[[@B71-ijms-21-04852]\]                                  

  11%        \[[@B79-ijms-21-04852]\]                                  

  1.6%       \[[@B72-ijms-21-04852]\]                                  

  1.5%       \[[@B69-ijms-21-04852]\]                                  

  5.4%       \[[@B73-ijms-21-04852]\]                                  

  3.2%       \[[@B70-ijms-21-04852]\]                                  

  3.7%       \[[@B70-ijms-21-04852]\]                                  

  *FBXW7*    8.1%                       \[[@B80-ijms-21-04852]\]       3.4%

  8.3%       \[[@B81-ijms-21-04852]\]                                  

  *GSK3β*    --                         1.2%                           

  *SFRP*     --                         1.7%                           

  *WIF1*     --                         2.8%                           
  ----------------------------------------------------------------------------

ijms-21-04852-t002_Table 2

###### 

WNT/β -catenin pathway inhibitors in melanoma (preclinical study).

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                                                               Target\                                                                                     Research Model                                                                                                                               References
                                                                         Mode of Action                                                                                                                                                                                                                           
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  C59                                                                    porcupine inhibitor (synergizes with CTLA4-targeting antibodies in mouse melanoma models)   WM266 human melanoma cell line; B16/F10 mouse melanoma cell line; patient derived Hu-175, Hu-422, Hu-424, Hu-451 human melanoma cell lines   \[[@B176-ijms-21-04852]\]

  WNT-2Ab                                                                WNT2 antibody                                                                               LOX, FEMX melanoma cell lines;                                                                                                               \[[@B177-ijms-21-04852]\]

  FJ9                                                                    DVL inhibitor                                                                               LOX melanoma cell line                                                                                                                       \[[@B178-ijms-21-04852]\]

  G007-LK                                                                tankyrase\                                                                                  B16/F10 mouse melanoma cell line                                                                                                             \[[@B179-ijms-21-04852]\]
                                                                         inhibitor\                                                                                                                                                                                                                               
                                                                         (sensitizes melanoma to PD-1 immune checkpoint blockade)                                                                                                                                                                                 

  fisetin                                                                \(i\) GSK3-β\                                                                               B16F10 mouse melanoma cell line                                                                                                              \[[@B180-ijms-21-04852]\]
                                                                         inhibitor                                                                                                                                                                                                                                

  \(ii\) activator of GSK3-β, DKK1 and WIF-1; FZD and LRP5/6 inhibitor   451Lu human melanoma cells; athymic (*nu/nu*) female nude mice                              \[[@B181-ijms-21-04852]\]                                                                                                                    

  lupeol                                                                 blocking the translocation of β-catenin to the nucleus                                      Mel 928, Mel 1241 and Mel 1011 human melanoma cell lines                                                                                     \[[@B182-ijms-21-04852]\]

  pentoxifylline                                                         β-catenin                                                                                   DMBC11, 12, 17, 19, 21 patient-derived melanoma\                                                                                             \[[@B183-ijms-21-04852]\]
                                                                                                                                                                     cell lines                                                                                                                                   

  PKF115-584                                                             β-catenin                                                                                   SKMEL28, A375, BLM, SKMEL19 and 451Lu human melanoma cell lines                                                                              \[[@B100-ijms-21-04852]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-21-04852-t003_Table 3

###### 

Overview of clinical trials (current and past clinical trials) evaluating activity of drugs targeting WNT pathway in melanoma, colorectal cancer and hepatocellular carcinoma (<https://clinicaltrials.gov>).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                                                  Company                                   Target/Mode of Action                         Type of Cancer                                          Trial Identifier (phase/status)                                    Ref.
  --------------------------------------------------------- ----------------------------------------- --------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  WNT974\                                                   Array BioPharma                           porcupine inhibitor                           metastatic colorectal cancer                            NCT02278133\                                                       \[[@B184-ijms-21-04852],[@B185-ijms-21-04852]\]
  (with LGX818 & cetuximab)                                                                                                                                                                                 (Phase 1; Phase 2/completed;\                                      
                                                                                                                                                                                                            updated: October 2017)                                             

  LGK974\                                                   Novartis Pharmaceuticals                  porcupine inhibitor                           BRAF mutant colorectal cancer & melanoma                NCT01351103\                                                       \[[@B184-ijms-21-04852],[@B185-ijms-21-04852]\]
  (monotherapy or combined with PDR001)                                                                                                                                                                     (Phase 1\                                                          
                                                                                                                                                                                                            /recruiting; updated: June 2020)                                   

  ETC-1922159\                                              EDDC, A\*STAR Research Entities           porcupine inhibitor                           colorectal cancer                                       NCT02521844\                                                       \[[@B186-ijms-21-04852]\]
  (with pembrolizumab)                                                                                                                                                                                      (Phase 1/active, not recruiting;\                                  
                                                                                                                                                                                                            updated: October 2019)                                             

  CGX1321                                                   Curegenix, Inc.                           porcupine inhibitor                           colorectal adenocarcinoma\                              NCT03507998\                                                       \[[@B187-ijms-21-04852]\]
                                                                                                                                                    hepatocellular carcinoma                                (Phase 1/\                                                         
                                                                                                                                                                                                            recruiting; updated: May 2019)                                     

  CGX1321\                                                  Curegenix, Inc.                           porcupine inhibitor                           colorectal cancer                                       NCT02675946\                                                       \[[@B187-ijms-21-04852]\]
  (with pembrolizumab)                                                                                                                                                                                      (Phase1/\                                                          
                                                                                                                                                                                                            recruiting updated: September 2019)                                

  PRI-724                                                   Prism Pharma Co., Ltd.                    interaction of β-catenin and CBP\             colorectal cancer                                       NCT01302405\                                                       \[[@B188-ijms-21-04852]\]
                                                                                                                                                                                                            (Phase 1 terminated due to low enrollment, updated: August 2017)   

  DKN-01\                                                   Johannes Gutenberg University Mainz       DKK1 inhibitor                                hepatocellular carcinoma                                NCT03645980\                                                       none
  (monotherapy or combined with sorafenib)                                                                                                                                                                  (Phase 1; Phase 2/recruiting; updated:\                            
                                                                                                                                                                                                            August 2019)                                                       

  OMP-54F28 (ipafricept)\                                   OncoMed Pharmaceuticals, Inc.             FZD8 decoy receptor for WNT ligands           locally advanced or metastatic hepatocellular cancer\   NCT02069145\                                                       \[[@B189-ijms-21-04852]\]
  with sorafenib                                                                                                                                    solid tumors                                            (Phase 1/completed; updated: August 2017)                          

  OMP-54F28 (ipafricept)                                    NCT01608867\                                                                                                                                                                                                       
                                                            (Phase 1/completed; updated: July 2017)                                                                                                                                                                            

  OMP-18R5\                                                 OncoMed Pharmaceuticals                   FZD receptors\                                solid tumors                                            NCT01345201\                                                       \[[@B190-ijms-21-04852]\]
  (vantictumab)                                                                                       (1, 2, 5, 7, 8) inhibitors                                                                            (Phase 1/completed;\                                               
                                                                                                                                                                                                            updated: September 2016)                                           

  Foxy-5                                                    WntResearch AB                            WNT5A mimetic                                 colorectal cancer                                       NCT02655952\                                                       \[[@B191-ijms-21-04852],[@B192-ijms-21-04852]\]
                                                                                                                                                                                                            &\                                                                 
                                                                                                                                                                                                            NCT02020291\                                                       
                                                                                                                                                                                                            (Phase 1/completed; updated: December 2018)\                       
                                                                                                                                                                                                            NCT03883802\                                                       
                                                                                                                                                                                                            (Phase 2/recruiting; updated: April 2019)                          

  Metastatic colorectal cancer                                                                                                                                                                                                                                                 

  OMP-131R10\                                               OncoMed Pharmaceuticals, Inc.             anti-R-spondin3 antibody                      colorectal cancer                                       NCT02482441\                                                       \[[@B193-ijms-21-04852]\]
  (with FOLFIRI)                                                                                                                                                                                            (Phase 1/completed; updated: August 2018)                          

  niclosamide                                               Michael Morse, MD                         FZD1 internalization and BCL-9 inhibition,\   colorectal cancer                                       NCT02687009\                                                       \[[@B194-ijms-21-04852],[@B195-ijms-21-04852],[@B196-ijms-21-04852],[@B197-ijms-21-04852],[@B198-ijms-21-04852],[@B199-ijms-21-04852],[@B200-ijms-21-04852]\]
                                                                                                      c-JUN upregulation                                                                                    (Phase 1/terminated, updated: February 2020)                       

  Charite University, Berlin, Germany                       metastatic colorectal cancer              NCT02519582\                                  \[[@B201-ijms-21-04852]\]\                                                                                                 
                                                                                                      (Phase 2\                                                                                                                                                                
                                                                                                      /recruiting; updated: September 2018)                                                                                                                                    

  genistein                                                 Sofya Pintova                             GSK3-β inhibitor\                             colorectal cancer                                       NCT01985763\                                                       \[[@B202-ijms-21-04852],[@B203-ijms-21-04852]\]
                                                                                                                                                                                                            (Phase 1; Phase 2/completed; updated: May 2019)                    

  resveratrol                                               University of California, Irvine          β-catenin/TCF interaction                     colorectal cancer                                       NCT00256334\                                                       \[[@B204-ijms-21-04852]\]
                                                                                                                                                                                                            (Phase 1/completed updated: June 2014)                             

  curcumin\                                                 Ente Ospedaliero Ospedali Galliera        β-catenin/TCF interaction                     colorectal adenoma                                      NCT01948661\                                                       \[[@B205-ijms-21-04852]\]
  (dietary supplements: Mirtoselect^®®®®^ & Meriva^®®®®^)                                                                                                                                                   (Phase not applicable, trial without FDA-defined phases\           
                                                                                                                                                                                                            /active, not recruiting; updated: August 2018)                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EDDC, Experimental Drug Development Center.
